6q deletion is frequent but unrelated to patient prognosis in breast cancer.

Autor: Lebok P; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany., Bönte H; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany., Kluth M; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany., Möller-Koop C; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany., Witzel I; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Wölber L; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Paluchowski P; Department of Gynecology, Regio Clinic Pinneberg, Pinneberg, Germany., Wilke C; Department of Gynecology, Regio Clinic Elmshorn, Elmshorn, Germany., Heilenkötter U; Department of Gynecology, Clinical Centre Itzehoe, Itzehoe, Germany., Müller V; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Schmalfeldt B; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Simon R; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. R.Simon@uke.de., Sauter G; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany., Terracciano L; Department of Pathology, Basel University Clinics, Basel, Switzerland., Krech RH; Institute of Pathology, Clinical Centre Osnabrück, Osnabrück, Germany., von der Assen A; Breast Centre Osnabrück, Osnabrück, Germany., Burandt E; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Jazyk: angličtina
Zdroj: Breast cancer (Tokyo, Japan) [Breast Cancer] 2022 Mar; Vol. 29 (2), pp. 216-223. Date of Electronic Publication: 2021 Oct 08.
DOI: 10.1007/s12282-021-01301-5
Abstrakt: Background: Deletions involving the long arm of chromosome 6 have been reported to occur in breast cancer, but little is known about the clinical relevance of this alteration.
Methods: We made use of a pre-existing tissue microarray with 2197 breast cancers and employed a 6q15/centromere 6 dual-labeling probe for fluorescence in situ (FISH) analysis RESULTS: Heterozygous 6q15 deletions were found in 202 (18%) of 1099 interpretable cancers, including 19% of 804 cancers of no special type (NST), 3% of 29 lobular cancers, 7% of 41 cribriform cancers, and 28% of 18 cancers with papillary features. Homozygous deletions were not detected. In the largest subset of NST tumors, 6q15 deletions were significantly linked to advanced tumor stage and high grade (p < 0.0001 each). 6q deletions were also associated with estrogen receptor negativity (p = 0.0182), high Ki67 proliferation index (p < 0.0001), amplifications of HER2 (p = 0.0159), CCND1 (p = 0.0069), and cMYC (p = 0.0411), as well as deletions of PTEN (p = 0.0003), 8p21 (p < 0.0001), and 9p21 (p = 0.0179). However, 6q15 deletion was unrelated to patient survival in all cancers, in NST cancers, or in subsets of cancers defined by the presence or absence of lymph-node metastases.
Conclusion: Our data demonstrate that 6q deletion is a frequent event in breast cancer that is statistically linked to unfavorable tumor phenotype and features of genomic instability. The absence of any prognostic impact argues against a clinical applicability of 6q15 deletion testing in breast cancer patients.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: